Back to Search Start Over

Predictive value of sentinel lymph node biopsy prior to neoadjuvant chemotherapy in clinically node negative breast cancer

Predictive value of sentinel lymph node biopsy prior to neoadjuvant chemotherapy in clinically node negative breast cancer

Authors :
J. T. Rabban
Barbara L. Smith
Beth Ann Lesnikoski
Marissa Howard-McNatt
Esther Rhei
Carolyn M. Kaelin
Julie L. Jones
Michele A. Gadd
Kevin S. Hughes
Roger L. Christian
Source :
Journal of Clinical Oncology. 22:606-606
Publication Year :
2004
Publisher :
American Society of Clinical Oncology (ASCO), 2004.

Abstract

606 Background: Applicability and optimal timing of sentinel node biopsy (SNB) in breast cancer patients treated with neoadjuvant therapy is not yet known. SNB prior to neoadjuvant therapy is relatively untested, while SNB after neoadjuvant therapy is associated with lower mapping success and higher false negative rates. SNB prior to neoadjuvant therapy may give data useful in guiding systemic, radiation and surgical treatment decisions. Methods: 52 T2-T4, N0 breast cancer patients who had SNB prior to neoadjuvant therapy from 7/2000 to 10/2003 were reviewed. Initial 1° tumor size, SNB pathology, clinical response to therapy and findings at definitive surgery were examined. Results: 22 patients (42%) were SNB(-) and 21 had no further axillary treatment. None have recurred locally. 1 SNB(-) patient had tumor progression during chemo and a positive axillary node dissection (ALND). 30 patients (58%) were SNB(+); to date 26 have had ALND after neoadjuvant therapy; 1 with a micromet had no further surgery. At ...

Details

ISSN :
15277755 and 0732183X
Volume :
22
Database :
OpenAIRE
Journal :
Journal of Clinical Oncology
Accession number :
edsair.doi...........c986a17e08c834056d4fb90de6ff2bb4
Full Text :
https://doi.org/10.1200/jco.2004.22.90140.606